These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28137208)

  • 1. C. elegans as Model for Drug Discovery.
    Carretero M; Solis GM; Petrascheck M
    Curr Top Med Chem; 2017; 17(18):2067-2076. PubMed ID: 28137208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C. elegans in high-throughput drug discovery.
    O'Reilly LP; Luke CJ; Perlmutter DH; Silverman GA; Pak SC
    Adv Drug Deliv Rev; 2014 Apr; 69-70():247-53. PubMed ID: 24333896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An ultra high-throughput, whole-animal screen for small molecule modulators of a specific genetic pathway in Caenorhabditis elegans.
    Leung CK; Wang Y; Malany S; Deonarine A; Nguyen K; Vasile S; Choe KP
    PLoS One; 2013; 8(4):e62166. PubMed ID: 23637990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Caenorhabditis elegans the Magic Bullet for Anthelminthic Drug Discovery?
    Keiser J
    Trends Parasitol; 2015 Oct; 31(10):455-456. PubMed ID: 26422771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caenorhabditis elegans: a versatile platform for drug discovery.
    Artal-Sanz M; de Jong L; Tavernarakis N
    Biotechnol J; 2006 Dec; 1(12):1405-18. PubMed ID: 17109493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caenorhabditis elegans as a chemical screening tool for the study o f neuromuscular disorders. Manual and semi-automated methods.
    Giacomotto J; Ségalat L; Carre-Pierrat M; Gieseler K
    Methods; 2012 Jan; 56(1):103-13. PubMed ID: 22041718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole animal HTS of small molecules for antifungal compounds.
    Muhammed M; Arvanitis M; Mylonakis E
    Expert Opin Drug Discov; 2016; 11(2):177-84. PubMed ID: 26593386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug discovery: Insights from the invertebrate Caenorhabditis elegans.
    Giunti S; Andersen N; Rayes D; De Rosa MJ
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00721. PubMed ID: 33641258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caenorhabditis elegans-based model systems for antifungal drug discovery.
    Anastassopoulou CG; Fuchs BB; Mylonakis E
    Curr Pharm Des; 2011; 17(13):1225-33. PubMed ID: 21470110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput small-molecule screening in Caenorhabditis elegans.
    Rangaraju S; Solis GM; Petrascheck M
    Methods Mol Biol; 2015; 1263():139-55. PubMed ID: 25618342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs.
    Kim W; Hendricks GL; Lee K; Mylonakis E
    Expert Opin Drug Discov; 2017 Jun; 12(6):625-633. PubMed ID: 28402221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective drug combination for
    Ding X; Njus Z; Kong T; Su W; Ho CM; Pandey S
    Sci Adv; 2017 Oct; 3(10):eaao1254. PubMed ID: 28983514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Dranchak PK; Oliphant E; Queme B; Lamy L; Wang Y; Huang R; Xia M; Tao D; Inglese J
    Dis Model Mech; 2023 Mar; 16(3):. PubMed ID: 36786055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of ML358, a Selective Small Molecule Inhibitor of the SKN-1 Pathway Involved in Drug Detoxification and Resistance in Nematodes.
    Peddibhotla S; Fontaine P; Leung CK; Maloney P; Hershberger PM; Wang Y; Bousquet MS; Luesch H; Mangravita-Novo A; Pinkerton AB; Smith LH; Malany S; Choe K
    ACS Chem Biol; 2015 Aug; 10(8):1871-9. PubMed ID: 25946346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A high-content assay for identifying small molecules that reprogram C. elegans germ cell fate.
    Benson JA; Cummings EE; O'Reilly LP; Lee MH; Pak SC
    Methods; 2014 Aug; 68(3):529-35. PubMed ID: 24990146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caenohabditis elegans in Parkinson's disease drug discovery: addressing an unmet medical need.
    Nass R; Merchant KM; Ryan T
    Mol Interv; 2008 Dec; 8(6):284-93. PubMed ID: 19144901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C. elegans: an all in one model for antimicrobial drug discovery.
    Squiban B; Kurz CL
    Curr Drug Targets; 2011 Jun; 12(7):967-77. PubMed ID: 21366520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling molecular and cellular aspects of human disease using the nematode Caenorhabditis elegans.
    Silverman GA; Luke CJ; Bhatia SR; Long OS; Vetica AC; Perlmutter DH; Pak SC
    Pediatr Res; 2009 Jan; 65(1):10-8. PubMed ID: 18852689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C. elegans for anti-infective discovery.
    Arvanitis M; Glavis-Bloom J; Mylonakis E
    Curr Opin Pharmacol; 2013 Oct; 13(5):769-74. PubMed ID: 23993686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing zebrafish chemical screens.
    Peterson RT; Fishman MC
    Methods Cell Biol; 2011; 105():525-41. PubMed ID: 21951546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.